Editor’s choice-biomarkers of acute cardiovascular and pulmonary diseases

European Heart Journal: Acute Cardiovascular Care

Volumn 5, Issue 5, 2016, Pages 416-433

  Suzuki, Toru ^a,b,c   Lyon, Alexander ^d,e   Saggar, Rajeev ^f   Heaney, Liam M ^b,c   Aizawa, Kenichi ^a   Cittadini, Antonio ^g   Mauro, Ciro ^h   Citro, Rodolfo ⁱ   Limongelli, Giuseppe ^j   Ferrara, Francesco ⁱ   Vriz, Olga ^k   Morley Smith, Andrew ^d,e   Calabrò, Paolo ^j   Bossone, Eduardo ⁱ  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c GLENFIELD HOSPITAL   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f Banner Good Samaritan Hospital   (United States)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h AORN A Cardarelli   (Italy)

ⁱ University Hospital   (Italy)

^j SECOND UNIVERSITY OF NAPLES   (Italy)

^k Sant Antonio Hospital   (Italy)

more..

Author keywords

Biomarkers; Chest disease; Critical care

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; PENTRAXIN 3; SURFACTANT PROTEIN D;

ADULT RESPIRATORY DISTRESS SYNDROME; AORTA DISSECTION; ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ECHOGRAPHY; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LUNG DISEASE; LUNG EMBOLISM; MYOCARDITIS; PERICARDITIS; PNEUMONIA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THORAX PAIN; THORAX RADIOGRAPHY; BLOOD; CARDIOVASCULAR DISEASES; DIFFERENTIAL DIAGNOSIS; HOSPITAL EMERGENCY SERVICE; LUNG DISEASES; METABOLISM;

BIOMARKERS; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; EMERGENCY SERVICE, HOSPITAL; HUMANS; LUNG DISEASES;

EID: 85016328702     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872616652309     Document Type: Article

References (129)

1. Boden WE and McKay RG. Optimal treatment of acute coronary syndromes-an evolving strategy. N Engl J Med 2001; 344: 1939-1342.
2. Yarlagadda RK and Boden WE. Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: Are we all becoming ‘interventional’ cardiologists? J Am Coll Cardiol 2002; 40: 1915-1918.
3. Murray CJ and Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
4. Katus HA, Remppis A, Looser S, et al. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989; 21: 1349-1353.
5. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315.
6. Steg PG, James SK, Atar D, et al.; Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
7. Reichlin T, Schindler C, Drexler B, et al. One-hour ruleout and rule-in of acute myocardial infarction using highsensitivity cardiac troponin T. Arch Intern Med 2012; 172: 1211-1218.
8. Suzuki T, Kohno H, Hasegawa A, et al.; Clinical Trial of Oxidized LDL (CTOL) Investigators. Diagnostic implications of circulating oxidized low density lipoprotein levels as a biochemical risk marker of coronary artery disease. Clin Biochem 2002; 35: 347-353.
9. Amaki T, Suzuki T, Nakamura F, et al. Circulating malondialdehyde modified LDL is a biochemical risk marker for coronary artery disease. Heart 2004; 90: 1211-1213.
10. Hayashida K, Kume N, Murase T, et al. Serum soluble lectin- like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: A novel marker for early diagnosis. Circulation 2005; 112: 812-818.
11. Inoue K, Sugiyama A, Reid PC, et al. Establishment of a high sensitivity plasma assay for human pentraxin3 as a marker for unstable angina pectoris. Arterioscler Thromb Vasc Biol 2007; 27: 161-167.
12. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106: 2894-2900.
13. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349: 1595-1604.
14. Kumarswamy R and Thum T. Non-coding RNAs in cardiac remodeling and heart failure. Circ Res 2013; 113: 676-689.
15. De Rosa S, Fichtlscherer S, Lehmann R, et al. Transcoronary concentration gradients of circulating microRNAs. Circulation 2011; 124: 1936-1944.
16. Wang GK, Zhu JQ, Zhang JT, et al. Circulating micro- RNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010; 31: 659-666.
17. D’Alessandra Y, Devanna P, Limana F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010; 31: 2765-2773.
18. Corsten MF, Dennert R, Jochems S, et al. Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 2010; 3: 499-506.
19. Widera C, Gupta SK, Lorenzen JM, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872-875.
20. Meder B, Keller A, Vogel B, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 2011; 106: 13-23.
21. Kuwabara Y, Ono K, Horie T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4: 446-454.
22. Jaguszewski M, Osipova J, Ghadri JR, et al. A signature of circulating microRNAs differentiates Takotsubo cardiomyopathy from acute myocardial infarction. Eur Heart J 2014; 35: 999-1006.
23. Caforio A, Pankuweit S, Arbustini E, et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648.
24. Jensen J, Ma LP, Fu ML, et al. Inflammation increases NT-proBNP and the NT-proBNP/BNP ratio. Clin Res Cardiol 2010; 99: 445-452.
25. Deswal A, Petersen NJ, Feldman AM, et al. Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001; 103: 2055-2059.
26. Deardorff R and Spinale FG. Cytokines and matrix metalloproteinases as potential biomarkers in chronic heart failure. Biomark Med 2009; 3: 513-523.
27. Emdin M, Vittorini S, Passino C, et al. Old and new biomarkers of heart failure. Eur J Heart Fail 2009; 11: 331-335.
28. Leone O, Veinot JP, Angelini A, et al. 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 2012; 21: 245-274.
29. Cooper LT, Baughman KL, Feldman AM, et al.; American Heart Association; American College of Cardiology; European Society of Cardiology; Heart Failure Society of America; Heart Failure Association of the European Society of Cardiology. The role of endomyocardial biopsy in the management of cardiovascular disease: A scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. J Am Coll Cardiol 2007; 50: 1914-1931.
30. Adler Y, Charron P, Imazio M, et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2015; 36: 2921-2964.
31. LeWinter MM. Clinical practice. Acute pericarditis. N Engl J Med 2014; 371: 2410-2416.
32. Imazio M, Brucato A, Maestroni S, et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: Implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation 2011; 123: 1092-1097.
33. Gamaza-Chulian S, Leon-Jimenez J, Recuerda-Nunez M, et al. Cardiac troponin-T in acute pericarditis. J Cardiovasc Med 2014; 15: 68-72.
34. Imazio M, Brucato A, Barbieri A, et al. Good prognosis for pericarditis with and without myocardial involvement: Results from a multicenter, prospective cohort study. Circulation 2013; 128: 42-49.
35. Pilgrim TM and Wyss TR. Takotsubo cardiomyopathy or transient left ventricular apical ballooning syndrome: A systematic review. Int J Cardiol 2008; 124: 283-292.
36. Citro R, Lyon AR, Meimoun P, et al. Standard and advanced echocardiography in takotsubo (stress) cardiomyopathy: Clinical and prognostic implications. J Am Soc Echocardiogr 2015; 28: 57-74.
37. Bossone E, Lyon A, Citro R, et al. Takotsubo cardiomyopathy: An integrated multi-imaging approach. Eur Heart J Cardiovasc Imaging 2014; 15: 366-377.
38. Wittstein IS, Thiemann DR, Lima JAC, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352: 539-548.
39. Madhavan M, Borlaug BA, Lerman A, et al. Stress hormone and circulating biomarker profile of apical ballooning syndrome (takotsubo cardiomyopathy): Insights into the clinical significance of B-type natriuretic peptide and troponin levels. Heart 2009; 95: 1436-1441.
40. Randhawa MS, Dhillon AS, Taylor HC, et al. Diagnostic utility of cardiac biomarkers in discriminating Takotsubo cardiomyopathy from acute myocardial infarction. J Card Fail 2014; 20: 377.e25-31.
41. Nascimento FO, Yang S, Larrauri-Reyes M, et al. Usefulness of the troponin-ejection fraction product to differentiate stress cardiomyopathy from ST-segment elevation myocardial infarction. Am J Cardiol 2014; 113: 429-433.
42. Frohlich GM, Schoch B, Schmid F, et al. Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy. Int J Cardiol 2012; 154: 328-332.
43. Murakami T, Yoshikawa T, Maekawa Y, et al.; CCU Network Scientific Committee. Characterization of predictors of in-hospital cardiac complications of Takotsubo cardiomyopathy: Multi-center registry from Tokyo CCU Network. J Cardiol 2014; 63: 269-273.
44. Citro R, Rigo F, D’Andrea A, et al.; Tako-Tsubo Italian Network Investigators. Echocardiographic correlates of acute heart failure, cardiogenic shock, and in-hospital mortality in Tako-tsubo cardiomyopathy. JACC Cardiovasc Imaging 2014; 7: 119-129.
45. Vriz O, Minisini R, Ruscio M, et al. ST2 marker might help to stratify in-hospital high risk patients with Tako-tsubo cardiomyopathy. Eur J Intern Med 2015; 26: 144-145.
46. Harris KM, Strauss CE, Eagle KA, et al.; International Registry of Acute Aortic Dissection (IRAD) Investigators. Correlates of delayed recognition and treatment of acute type A aortic dissection: The International Registry of Acute Aortic Dissection (IRAD). Circulation 2011; 124: 1911-1918.
47. Katoh H, Suzuki T, Hiroi Y, et al. Diagnosis of aortic dissection by immunoassay for circulating smooth muscle myosin. Lancet 1995; 345: 191-192.
48. Suzuki T, Katoh H, Tsuchio Y, et al. Diagnostic implications of elevated levels of smooth-muscle myosin heavychain protein in acute aortic dissection. The smooth muscle myosin heavy chain study. Ann Intern Med 2000; 133: 537-541.
49. Suzuki T, Katoh H, Watanabe M, et al. Novel biochemical diagnostic method for aortic dissection. Results of a prospective study using an immunoassay of smooth muscle myosin heavy chain. Circulation 1996; 93: 1244-1249.
50. Suzuki T, Katoh H, Kurabayashi M, et al. Biochemical diagnosis of aortic dissection by raised concentrations of creatine kinase BB-isozyme. Lancet 1997; 350: 784-785.
51. Suzuki T, Distante A, Zizza A, et al.; International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRADBio) Investigators. Preliminary experience with the smooth muscle troponin-like protein, calponin, as a novel biomarker for diagnosing acute aortic dissection. Eur Heart J 2008;29: 1439-1445.
52. Shinohara T, Suzuki K, Okada M, et al. Soluble elastin fragments in serum are elevated in acute aortic dissection. Arterioscler Thromb Vasc Biol 2003; 23: 1839-1844.
53. Sangiorgi G, Trimarchi S, Mauriello A, et al. Plasma levels of metalloproteinases-9 and -2 in the acute and subacute phases of type A and type B aortic dissection. J Cardiovasc Med 2006; 7: 307-315.
54. Kuehl H, Eggebrecht H, Boes T, et al. Detection of inflammation in patients with acute aortic syndrome: Comparison of FDG-PET/CT imaging and serological markers of inflammation. Heart 2008; 94: 1472-1477.
55. Makita S, Ohira A, Tachieda R, et al. Behavior of C-reactive protein levels in medically treated aortic dissection and intramural hematoma. Am J Cardiol 2000; 86: 242-244.
56. Sakakura K, Kubo N, Ako J, et al. Peak C-reactive protein level predicts long-term outcomes in type B acute aortic dissection. Hypertension 2010; 55: 422-429.
57. Matt P, Schoenhoff F, Habashi J, et al.; GenTAC Consortium. Circulating transforming growth factor-beta in Marfan syndrome. Circulation 2009; 120: 526-532.
58. Suzuki T, Trimarchi S, Sawaki D, et al. Circulating transforming growth factor-beta levels in acute aortic dissection. J Am Coll Cardiol 2011; 58: 775.
59. Stein PD, Hull RD, Patel KC, et al. D-dimer for the exclusion of acute venous thrombosis and pulmonary embolism: A systematic review. Ann Intern Med 2004; 140: 589-602.
60. Suzuki T, Distante A, Zizza A, et al.; IRAD-Bio Investigators. Diagnosis of acute aortic dissection by D-dimer: The International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRAD-Bio) experience. Circulation 2009; 119: 2702-2707.
61. Erbel R, Aboyans V, Boileau C, et al.; ESC Committee for Practice Guidelines. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014; 35: 2873-2926.
62. Maisel A. B-type natriuretic peptide levels: A potential novel ‘white count’ for congestive heart failure. J Card Fail 2001; 7: 183-193.
63. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355: 1126-1130.
64. Weinfeld MS, Chertow GM and Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 1999; 138: 285-290.
65. Maisel AS, Clopton P, Krishnaswamy P, et al.; BNP Multinational Study Investigators. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: Results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004; 147: 1078-1084.
66. Hunt SA, Abraham WT, Chin MH, et al.; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the diagnosis and management of heart failure in adults: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-e90.
67. McMurray JJ, Adamopoulos S, Anker SD, et al.; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology, ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-869.
68. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: Results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47: 91-97.
69. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007; 50: 607-613.
70. Shah RV, Chen-Tournoux AA, Picard MH, et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12: 826-832.
71. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48: 1217-1224.
72. Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 2007; 116: 258-267.
73. Goldraich LA, Martinelli NC, Matte U, et al. Transcoronary gradient of plasma microRNA 423-5p in heart failure: Evidence of altered myocardial expression. Biomarkers 2014; 19: 135-141.
74. Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035-1039.
75. Goren Y, Kushnir M, Zafrir B, et al. Serum levels of micro- RNAs in patients with heart failure. Eur J Heart Fail 2012; 14: 147-154.
76. Bauters C, Kumarswamy R, Holzmann A, et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 2013; 168: 1837-1840.
77. Bates SM, Jaeschke R, Stevens SM, et al.; American College of Chest Physicians. Diagnosis of DVT: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012; 141: e351S-e418S.
78. Konstantinides SV, Torbicki A, Agnelli G, et al.; Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033-3069.
79. Wells PS, Owen C, Doucette S, et al. Does this patient have deep vein thrombosis? JAMA 2006; 295: 199-207.
80. Righini M, Goehring C, Bounameaux H, et al. Effects of age on the performance of common diagnostic tests for pulmonary embolism. Am J Med 2000; 109: 357-361.
81. Righini M, Nendaz M, Le Gal G, et al. Influence of age on the cost-effectiveness of diagnostic strategies for suspected pulmonary embolism. J Thromb Haemost 2007; 5: 1869-1877.
82. Schouten HJ, Geersing GJ, Koek HL, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: Systematic review and meta-analysis. Br Med J 2013; 346: f2492.
83. Douma RA, le Gal G, Sohne M, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: A retrospective analysis of three large cohorts. Br Med J 2010; 340: c1475.
84. Righini M, Van Es J, Den Exter PL, et al. Age-adjusted D-dimer cutoff levels to rule out pulmonary embolism: The ADJUST-PE study. JAMA 2014; 311: 1117-1124.
85. Kruip MJ, Leclercq MG, van der Heul C, et al. Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med 2003; 138: 941-951.
86. Kline JA, Courtney DM, Kabrhel C, et al. Prospective multicenter evaluation of the pulmonary embolism rule-out criteria. J Thromb Haemost 2008; 6: 772-780.
87. Stein PD, Sostman HD, Bounameaux H, et al. Challenges in the diagnosis of acute pulmonary embolism. Am J Med 2008; 121: 565-571.
88. Stein PD, Sostman HD, Hull RD, et al. Diagnosis of pulmonary embolism in the coronary care unit. Am J Cardiol 2009; 103: 881-886.
89. Becattini C, Vedovati MC and Agnelli G. Prognostic value of troponins in acute pulmonary embolism: A meta-analysis. Circulation 2007; 116: 427-433.
90. Kucher N, Printzen G and Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003; 107: 2545-2547.
91. Xiao J, Jing ZC, Ellinor PT, et al. MicroRNA-134 as a potential plasma biomarker for the diagnosis of acute pulmonary embolism. J Transl Med 2011; 9: 159.
92. Wang M, Huang Y, Liang Z, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J 2016; 10: 104-111.
93. Ware LB and Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342: 1334-1349.
94. Ware LB, Koyama T, Billheimer DD, et al.; NHLBI ARDS Clinical Trials Network. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest 2010; 137: 288-296.
95. Pan T, Nielsen LD, Allen MJ, et al. Serum SP-D is a marker of lung injury in rats. Am J Physiol Lung Cell Mol Physiol 2002; 282: L824-L832.
96. Koch AE, Kunkel SL, Burrows JC, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991; 147: 2187-2195.
97. Huber AR, Kunkel SL, Todd RF 3rd, et al. Regulation of transendothelial neutrophil migration by endogenous interleukin- 8. Science 1991; 254: 99-102.
98. Schroder JM and Christophers E. Secretion of novel and homologous neutrophil-activating peptides by LPS-stimulated human endothelial cells. J Immunol 1989; 142: 244-251.
99. Calfee CS, Janz DR, Bernard GR, et al.; NIH NHLBI ARDS Network. Distinct molecular phenotypes of direct versus indirect ARDS in single and multi-center studies. Chest 2015; 147: 1539-1548.
100. Ware LB and Matthay MA. Clinical practice. Acute pulmonary edema. N Engl J Med 2005; 353: 2788-2796.
101. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365.
102. Camargo CA Jr and Rowe BH. Asthma exacerbations. In: Barnes PJ, Drazen JM, Rennard SI, et al. (eds) Asthma and COPD: basic mechanisms and clinical management. 2nd ed. Waltham, MA: Academic Press, 2008, pp. 775-789.
103. Mutlu LC, Altintas N, Aydin M, et al. Growth differentiation factor-15 is a novel biomarker predicting acute exacerbation of chronic obstructive pulmonary disease. Inflammation 2015; 38: 1805-1813.
104. Fruchter O, Yigla M and Kramer MR. D-dimer as a prognostic biomarker for mortality in chronic obstructive pulmonary disease exacerbation. Am J Med Sci 2015; 349: 29-35.
105. Patel ARC, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 188: 1091-1099.
106. Brims FJH, Chauhan AK, Higgins B, et al. Up-regulation of the extrinsic coagulation pathway in acute asthma - a case study. J Asthma 2010; 47: 695-698.
107. Bafadhel M, Clark TW, Reid C, et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community- acquired pneumonia or exacerbation of asthma or COPD. Chest 2011; 139: 1410-1418.
108. Lipinski MJ, Baker NC, Escarcega RO, et al. Comparison of conventional and high-sensitivity troponin in patients with chest pain: A collaborative meta-analysis. Am Heart J 2015; 169: 6-16.
109. Zhelev Z, Hyde C, Youngman E, et al. Diagnostic accuracy of single baseline measurement of Elecsys Troponin T high-sensitive assay for diagnosis of acute myocardial infarction in emergency department: Systematic review and meta-analysis. Br Med J 2015; 350: h15.
110. Raskovalova T, Twerenbold R, Collinson PO, et al. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: A systematic review and meta-analysis. Eur Heart J Acute Cardiovasc Care 2014; 3: 18-27.
111. Ricci F, Di Scala R, Massacesi C, et al. Ultra-sensitive copeptin and cardiac troponin in diagnosing non-ST-elevation acute coronary syndromes - the COPACS Study. Am J Med 2016; 129: 105-114.
112. Roberts E, Ludman AJ, Dworzynski K, et al.; NICE Guideline Development Group for Acute Heart Failure. The diagnostic accuracy of the natriuretic peptides in heart failure: Systematic review and diagnostic meta-analysis in the acute care setting. Br Med J 2015; 350: h910.
113. Asha SE and Miers JW. A systematic review and metaanalysis of D-dimer as a rule-out test for suspected acute aortic dissection. Ann Emerg Med 2015; 66: 368-378.
114. Gorla R, Erbel R, Kahlert P, et al. Accuracy of a diagnostic strategy combining aortic dissection detection risk score and D-dimer levels in patients with suspected acute aortic syndrome. Eur Heart J Acute Cardiovasc Care 2015. Epub ahead of print 16 July 2015. DOI: 10.1177/2048872615594497
115. Heidenreich PA, Alloggiamento T, Melsop K, et al. The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: A meta-analysis. J Am Coll Cardiol 2001; 38: 478-485.
116. Troughton RW, Frampton CM, Brunner-La Rocca HP, et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: An individual patient meta-analysis. Eur Heart J 2014; 35: 1559-1567.
117. Braga JR, Tu JV, Austin PC, et al. Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation. Circ Heart Fail 2013; 6: 193-202.
118. Parissis JT, Papadakis J, Kadoglou NP, et al. Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels. Int J Cardiol 2013; 168: 3609-3612.
119. Huang B, Yang Y, Lu H, et al. Impact of d-Dimer levels on admission on inhospital and long-term outcome in patients with type A acute aortic dissection. Am J Cardiol 2015; 115: 1595-1600.
120. Wen D, Du X, Dong JZ, et al. Value of D-dimer and C reactive protein in predicting inhospital death in acute aortic dissection. Heart 2013; 99: 1192-1197.
121. Klok FA, Mos IC and Huisman MV. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: A systematic review and metaanalysis. Am J Respir Crit Care Med 2008; 178: 425-430.
122. Lankeit M, Jimenez D, Kostrubiec M, et al. Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism. Eur Respir J 2014; 43: 1669-1677.
123. Lankeit M, Jimenez D, Kostrubiec M, et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: A prospective validation study. Circulation 2011; 124: 2716-2724.
124. Dellas C, Puls M, Lankeit M, et al. Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol 2010; 55: 2150-2157.
125. Inoue K, Suwa S, Ohta H, et al. Heart fatty acid-binding protein offers similar diagnostic performance to high-sensitivity troponin T in emergency room patients presenting with chest pain. Circ J 2011; 75: 2813-2820.
126. Moe GW, Ezekowitz JA, O’Meara E, et al.; Canadian Cardiovascular Society. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, biomarkers, and recent therapeutic trial implications. Can J Cardiol 2015; 31: 3-16.
127. Kohno N, Kyoizumi S, Awaya Y, et al. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989; 96: 68-73.
128. Yokoyama A, Kondo K, Nakajima M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006; 11: 164-168.
129. Stahel RA, Gilks WR, Lehmann HP, et al. Third International Workshop on Lung Tumor and Differentiation Antigens: Overview of the results of the central data analysis. Int J Cancer Suppl 1994; 8: 6-26.